Introduction
============

As an organ in upper digestive tract, the stomach is responsible for digestion and decomposition of food; while the colorectum, as an organ in lower digestive tract, mainly absorb water and electrolytes, and store fecal material until it is evacuated. They have similarities in anatomical structure and organizational level. Despite their own characteristics, the stomach and colorectum are interacted with each other.

Although the incidence of gastric cancer (GC) and colorectal cancer (CRC) has different trends in the Western population: a marked decrease has been observed in GC during last decades in many countries, while a stable or increasing trend has been described for CRC [@B1], there have been epidemiological studies showing that the upper and lower gastrointestinal organs (stomach, colon and rectum) have many similarities in the genesis and development of cancer. For example, changing diet, activity patterns and smoking are involved in their carcinogenesis [@B1]. Moreover, they have some tumor markers in common [@B2], [@B3], such as CEA, CA199, CDX2, etc. Therefore, it is reasonable to infer that some similar functional factors may participate in the development of GC and CRC. As we know, GC can be divided into intestinal and diffuse types histologically. Intestinal-type GC (IGC) is based on the intestinal metaplasia of gastric mucosa. Newbold [@B4] suggested common histogenesis between IGC and CRC by demonstrating that similar clusters of undifferentiated proliferating columnar cells occurred in the mucosal surfaces associated with intestinal metaplasia in stomach and adenomatous polyps in colorectum. It has been paid great attention to whether IGC and CRC have function alteration in common [@B5]-[@B7].

Pepsinogen (PG) and gastrin (G-17) are secreted by gastric mucosa and a fraction of them are released into blood. Detection of the secreted protein (PGs, G-17) levels in serum can indirectly evaluate the function status of stomach.*H. pylori* can cause immune response and induce drug resistance after infection in human body. It would improve the knowledge of *H. pylori* infection status of stomach to examine its antibody (*Hp*Ab) in serum. Previously, a lot of researches have suggested that the serum markers reflecting gastric function (PGs, G-17) and *H. pylori* infection (*Hp-*IgG) play important roles in GC screening as serological biopsy, especially for IGC and gastric precancerous diseases [@B8]-[@B10]. However, it remains unclear whether the function of upper digestive tract organs may affect lower tract organs and whether GC-related risk markers also indicate an increased risk of CRC.

Here, we conducted a hospital-based case-control study to clarify the association of serum markers reflecting gastric function and *H. pylori* infection with CRC, including pepsinogen (PGI, PGII, PGI/II ratio), G-17 and *Hp-*IgG, aiming to explore the clinical significance of these serum markers in CRC.

Materials and Methods
=====================

Study population
----------------

The present study was approved by the Human Ethics Review Committee of The First Hospital of China Medical University (Shenyang, China). Informed consent was obtained from all participants. The cases (n=569) were diagnosed with CRC after surgery in the Anorectal Surgery Department of The First Hospital of China Medical University between June 2012 and April 2016. Controls (n=569) were randomly selected from the cancer-free individuals seeking for physical examination in the Medical Examination Department in The First Hospital of China Medical University during the same period. The controls were frequency-matched to the cases based on gender and age (±5 years).

A total of 625 CRC cases were recruited in our study initially. According to the inclusion and exclusion criteria, 569 cases were finally enrolled after removal of the individuals that refused to get involved. Inclusion criteria: i) CRC cases were diagnosed by postoperative pathology, combined with imaging examination for staging, all cases were diagnosed as adenocarcinoma; ii) No preoperative chemotherapy, radiation therapy and any anti-tumor treatment; iii) No malignant tumors of other systems and no distant metastasis; iv) No history of upper gastrointestinal diseases; v) Information in medical records was complete. Exclusion criteria: i) Previous surgery, radiotherapy, chemotherapy; ii) Severe comorbidities, including hepatic, renal, cardiopulmonary, and hematologic diseases; iii) Preoperative distant metastasis or primary tumor of other organs; iv) History of basic diseases in the digestive tract; v) Non-radical surgery; vi) Incomplete information in medical records.

A total of 2004 controls were recruited in our study initially. According to the inclusion and exclusion criteria, 569 controls were finally enrolled after removal of the individuals that refused to get involved. Inclusion criteria: i) No abnormality in regular imaging examination (e.g. lung CT, abdominal CT); ii) No abnormality in routine test (e.g. blood routine, liver and kidney function, tumor biomarkers); iii) No malignancy in any system; iv) No history of upper gastrointestinal diseases; v) Information in medical records was complete. Exclusion criteria: i) Abnormality in imaging examination or tests; ii) History of malignancy in any system; iii) History of severe diseases, including hepatic, renal, cardiopulmonary and hematologic diseases; iv) History of basic diseases in the digestive tract; v) Information in medical records was incomplete.

Serological detection
---------------------

Fasting venous blood samples (5mL) were collected from each CRC case for detection of serum markers reflecting gastric function and *H. pylori* infection before surgery (average 7 days) after admission. Fasting venous blood samples (5mL) were also collected from controls when they visited Medical Examination Department.

Samples were centrifuged immediately at 3,500g for 10 minutes, and serum aliquot was immediately frozen and stored at -80°C until analysis. Serum PGI, PGII, G-17 and *Hp-*IgG were detected using enzyme-linked immunosorbent assays (BIOHIT Plc, Helsinki, Finland) according to the manufacturer\'s protocols. Samples that yielded implausible values were re-tested. Duplicate negative and positive controls were included in each 96-well plate. The mean intra-assay coefficients of variation (CV) were 11% for PGI, 12% for PGII, 15% for gastrin-17 and 11% for *Hp-*IgG. The test items and reference ranges were set as the followings: PGI: \>70ug/L; PGII: \<8.5ug/L; PGI/II ratio \>7; G-17: 0-5.5pmol/L [@B9], [@B11], [@B12]; Serum *Hp-*IgG antibody titer ≥35EIU was determined as positive *Hp-*IgG, according to the manufacturer\'s reagent specification (ELISA kits; BIOHIT Plc, Helsinki, Finland).

The information of serum tumor biomarkers of all the subjects was collected from medical records. The test items and reference ranges were set as the followings: CEA: 0-4.3ng/ml; AFP: 0-7ng/mL; CA125: 0-35U/mL; CA153: 0-25 U/mL; CA199: 0-27 U/mL, according to the manufacturer\'s reagent specification (CEA, AFP, CA125, CA153, CA199 Antigen Quantitative Assay Kit (Electrochemiluminescence), Roche Diagnostics GmbH).

Clinicopathological information collection
------------------------------------------

*Clinicopathological* data collection was performed according to the AJCC TNM system (7th edition, 2010)[@B13] and parameters such as histopathological grade, gross type, depth of infiltration, lymph node metastasis, TNM stage, growth mode, vascular carcinoma embolus, perineural invasion and ENTD (extranodal tumor deposits) were taken notes.

Statistical analysis
--------------------

Continuous variables were presented as median (25th to 75th percentiles). Categorical variables were compared between groups using Chi-square test and multiple logistic regression. Regardless of unavailable information of other CRC risk factors, the odds ratios (ORs) with 95% confidence intervals (95%CIs) were calculated to evaluate the association adjusted by age and sex. Additionally, heterogeneity tests were conducted for stratification analysis using the Episheet (Spreadsheets for the Analysis of Epidemiologic Data, written by Ken Rothman, Version of October 4, 2012). The Bonferroni correction was adopted to adjust P values for multiple comparisons. The remaining statistical analyses were performed using SPSS 22.0 software. P\<0.05 (two-sided) was considered to be statistically significant.

Results
=======

Baseline characteristics of the study participants
--------------------------------------------------

The CRC and control groups were matched based on age (*P*=0.055) and gender (*P*=0.107). The baseline characteristics of the study participants were presented in Table [1](#T1){ref-type="table"}.

Association of serum markers reflecting gastric function and *H. pylori* infection with CRC risk
------------------------------------------------------------------------------------------------

Overall analysis for the levels of serum markers reflecting gastric function and *H. pylori* infection between CRC cases and controls was presented in Table [2](#T2){ref-type="table"}. Compared with the controls, serum PGII, G-17 and *Hp-*IgG was higher in CRC cases (*P*=0.006,*P*\<0.001, *P*=0.001 respectively). No significant difference in PGI and PGI/II ratio was found between CRC cases and controls.

To identify other factors that may affect the gastric function indicators, we also analyzed the correlation among the gastric function markers and *Hp-*IgG, and found there are some correlation exist, we list the results in (Table [S1](#SM0){ref-type="supplementary-material"}). In addition, the association analyses were also performed adjusted by all the gastric function indicators other than age and sex unless one of them was regarded as the analyzed item. Similar results could be observed. Serum PGI/II, G-17 and *Hp-*IgG were higher in CRC cases than the controls (Table [S2](#SM0){ref-type="supplementary-material"}).

Stratified analysis for the levels of serum markers reflecting gastric function and *H. pylori* infection between CRC cases and controls was presented in Table [3](#T3){ref-type="table"}. PGII was more significant in the subgroup of males (*P*=0.014, *P*~heterogeneity~=0.362). *Hp-*IgG demonstrated a higher association with CRC in the subgroup of age\<60y (*P*=0.001, *P*~heterogeneity~=0.094). G-17 was more significant in the *Hp-*IgG negative subgroup (*P\<*0.001, *P*~heterogeneity~*\<*0.001). PGII and PGI/II ratio were positively associated with CRC in the *Hp-*IgG negative subgroup and inversely associated in the *Hp-*IgG positive subgroup (P~heterogeneity~=*\<*0.001 and *\<*0.001, respectively).

Association of serum markers reflecting gastric function and *H. pylori* infection with tumor biomarkers
--------------------------------------------------------------------------------------------------------

The relationship of PGI, PGII, PGI/II ratio, G-17 and *Hp-*IgG levels with serum tumor biomarkers in CRC cases was presented in Table [4](#T4){ref-type="table"}. All the cases with available information of tumor biomarkers in medical records were analyzed (CEA 429 cases, AFP 426 cases, CA125 428 cases, CA153 424 cases and CA199 428 cases). Significant positive association was found between G-17 and CA125 (*P*=0.005), as well as *Hp-*IgG and CA125 (*P*=0.024). No association was observed in the serum levels of PGI, PGII and PGI/II ratio with tumor biomarkers.

Association of serum markers reflecting gastric function and *H. pylori* infection with CRC clinicopathological parameters
--------------------------------------------------------------------------------------------------------------------------

The relation of gastric function indicators and *Hp-*IgG to CRC clinicopathological parameters was presented in Table [S4](#SM0){ref-type="supplementary-material"}. Totally, 556 CRC cases with complete clinicopathological parameters information were involved in the analysis. However, no significance was indicated between gastric function indicators, *Hp-*IgG and any of the CRC clinicopathological parameters assessed.

Discussion
==========

To explore the clinical significance of serum markers reflecting gastric function and *H. pylori* infection in CRC, we investigated the association of serum PGI, PGII, G-17 and *Hp-*IgG with CRC risk, tumor biomarkers and CRC clinicopathological parameters, aiming to provide the basis for diagnosis and treatment of CRC by applying these functional indicators. As far as we concern, this is the first report on the clinical significance of all gastric function indicators together combined with CRC.

As important organs of the whole digestive tract, both stomach and colorectum have not only anatomical structural similarities, but also functional correlations. As we know, PGs are specific products in the terminal differentiation of gastric mucosa. They are of diagnostic value for atrophic gastritis and have some roles as risk markers and screening tools for GC [@B14]. In our study, the association of PGI, PGII and PGI/II ratio with CRC was explored. PGI is mainly secreted by chief cells in the fundic mucosa, and is generally applied to evaluate the function in different sites of gastric mucosa. A long term follow-up study[@B15] and a case-control study[@B16] reported no association between serum PGI level and CRC. In the present study, we found that the serum level of PGI did not indicate relations to CRC risk which is similar to previous results. PGII is secreted by pyloric glands and proximal duodenal mucosa. Previous studies suggested that the serum PG assay was more beneficial for the screening of IGC than for the diffuse-type GC, especially in the case of a high PG II level [@B17]. In the present study we found a higher level of PGII in CRC. Sushil Kumar et al [@B18] had reported that patients with IM had higher level of PG II than those without IM. Intestinal metaplasia might cause hypochlorhydria which hampers protein assimilation, increases some metabolites and unabsorbed nutrients, leads to bacterial overgrowth and colonic disorders, and thus affects the internal environment and intestinal function, being related to intestinal tumorigenesis [@B19], [@B20]. In view of these findings, it can be inferred that PGII may promote intestinal metaplasia, affect intestinal mucosa through similar mechanism and thus result in CRC initiation. PGI/II ratio is very valuable in predicting the development of atrophic gastritis [@B21] and GC [@B22]. Yanaoka, Oka et al. reported that PGI/II ratio was a reliable marker for intestinal-type GC [@B23]. Dinis-Ribeiro et al [@B24] found that PGI/II ratio would be significantly decreased with carcinogenesis (type II, type III IM or low-grade dysplasia). However, in the present study we found that the serum level of PGI/II ratio did not indicate relations to CRC risk. Up to now, no research has reported the correlation between PGI/II ratio and CRC risk. It is necessary to expand further studies to verify our initial results. In addition to the overall analysis, we did a subgroup analysis based on different ages and genders in our study. Only PGII was found more significant in the males. Many epidemiological investigations have shown that the prevalence and mortality of CRC are higher in men than in women. Such disparities can be attributed to gender-specific lifestyle and behavioral characteristics which can influence the effects of exposure to genotoxins. Our finding that the serum PGII levels were higher in male subjects than in female subjects is in agreement with some earlier studies, such as an study in health check-up population [@B25] and another one in different gastric diseases population [@B11]. These data suggested that in clinical applications, it could be preferable to set different reference values for males and females.

As a peptide hormone and trophic factor, gastrin has been suggested to play a growth-promoting role in gastrointestinal malignancy in addition to regulating gastric acid secretion [@B26]. Gastrin and its receptor were expressed in the gastric mucosa of patients with premalignant lesions of the lower gastrointestinal tract [@B27], and the gastrin system might also be able to promote colon carcinogenesis [@B28]. Although previous research had investigated on the relationship of gastrin with colorectal neoplasia, the results were inconsistent [@B15], [@B16], [@B28]-[@B30]. In the present study we found that G-17 had higher level in CRC. It has been suggested that the elevation of gastrin secretion could increase the modification of gut microbiota and cause the chronic inflammation status of the intestine [@B31]. Chronic inflammation exerts tumorigenic effects via production of cytokines, chemokines, growth factors, reactive oxygen species and nitrogen intermediates by immune cells [@B32]. These can lead to hyper-proliferation and resistance of pre-malignant cells to apoptosis, affect epithelial permeability, cause epigenetic alterations and inactivation of DNA repair mechanisms, and influence anti-tumor immune responses [@B33], [@B34]. Moreover, colorectal carcinoma cells could aberrantly generate gastrin as well. Hence, gastrin may act as an autocrine/paracrine or endocrine factor in the initiation and progression of colorectal carcinoma [@B26].

Regarding the association between *H. pylori* infection and CRC risk, the results in different literature were inconsistent. Several meta-analyses [@B35]-[@B37] suggested increased CRC risk associated with *H. pylori* infection. However, some findings did not support a significant association between *H. pylori* infection and CRC [@B38]-[@B40]. In our study, the serum *Hp-*IgG was higher in CRC cases than in controls, especially in the subgroup of age\<60y. A prospective cohort study found that *H. pylori* infection was associated with a 60-80% increase in CRC risk and this association was particularly strong with colon cancer diagnosed at \<55 years of age [@B41]. It is well accepted that gastric adenocarcinoma, especially the intestinal-type, is based on a long-term precancerous course promoted by *H. pylori* [@B42]. Most CRC cases derive from adenomas, and *H. pylori*-related IM was identified as an independent risk factor for colorectal adenoma in Chinese older than 40y [@B43]. Therefore, *H. pylori* may act alone or have synergistic effect with other carcinogenic molecules to promote the development of CRC. *H. pylori*-induced inflammatory changes in colonic mucosa [@B44] is probably related to inflammation and cytokine release. Considering that chronic inflammation caused by *H. pylori* infection could increase gastrin secretion [@B45], [@B46], in our study, *Hp-*IgG was regarded as an adjustment factor in the analysis of G-17. In stratification analysis, we found G-17 was only significantly associated with CRC in the *Hp-*IgG negative subgroup (*P*\<0.001). This finding is different from the results obtained in similar studies conducted in different gastric disease populations. In addition to *H. pylori* infection, the level of gastrin in serum is affected by many factors, such as age and gender, etc. Our results show that *H. pylori* infection has a lower effect on serum gastrin levels in CRC cases than in the controls, suggesting that the risk effect of G-17 on CRC was more obvious in the *H. pylori* negative population.

We explored the association of PGI, PGII, PGI/II ratio, G-17 and *Hp-*IgG levels with serum tumor biomarkers. The results showed that G-17 was associated with CA125 positivity (P=0.005). *Hp-*IgG was associated with CA125 (P=0.024) positivity. However, no statistically significant association was observed in the serum levels of PGI, PGII and PGI/II ratio with CEA, AFP, CA125, CA153 or CA199.CA-125 was a representative biomarker of ovarian cancer and was expected to be applied as a screening tool in patients at risk of ovarian cancer. CA125 and pro-gastrin-releasing peptide (ProGRP) were reported to be increased simultaneously in patients with advanced lung adenocarcinoma[@B47]. G-17, which can promote the secretion in the gastrointestinal tract, and the release of insulin and calcitonin, may also increase the serum level of CA125 related to endocrine system and hormone levels. The association between G-17 and CA125 in CRC suggested that G-17 might play an important role in hormone regulation of CRC. It not only has a possible diagnostic value but also could be beneficial to CRC therapy from the perspective of endocrinology, which is a very interesting topic in further investigation. Most cancer derives from chronic inflammation and tumor microenvironment, which is an important participant in the neoplastic process mainly induced by inflammatory cells. *H.pylori* infection might affect inflammation status. In view of the association between *H.pylori* and tumor biomarkers in CRC, we speculate that *H.pylori* may also play a role in colorectal carcinogenesis.

Lastly, we analyzed the association between serological marker levels and clinicopathological parameters of CRC. However, no significance was indicated between gastric function indicators, *Hp-*IgG and any of the CRC clinicopathological parameters assessed.

Some limitations should be acknowledged in our study. First, the study design is retrospective and observational, which has inherent limitations. Given that serum samples were collected once the CRC was present, the disease could have caused the modification in the markers instead of the opposite hypothesis. As a result, it is inevitable to discard a possible reverse causation. Secondly, all the subjects are hospital-based, which may cause selection bias. The controls were volunteering attending to the Medical Examination Department, thus they had more symptoms than the general population bringing them to seek health checking, which might lead to some underestimation of a possible association between the markers studied and CRC. Moreover, the low participation rate among controls could also increase the risk of selection bias, resulting in the difference of serum markers level between study subjects and general population. Thirdly, we had not data on potential confounding factors, especially the information about other CRC risk factors including obesity, diet, smoking, physical activity, family history, red and processed meat intake, fruit and vegetables intake, etc. Furthermore, our research is only focused on the association study without in-depth investigation about involved mechanisms. In the future, functional studies are needed to explore the specific mechanism to verify our results.

In summary, we explored the clinical significance of serum markers reflecting gastric function and *H. pylori* infection in colorectal cancer. It was shown that the aberrant indicators PGII, G-17 and *Hp-*IgG might be associated with an increased CRC risk; G-17 and *Hp-*IgG were associated with some tumor biomarkers; Therefore, the serum markers reflecting gastric function and *H. pylori* infection might serve as indirect indicators of intestinal function, and may provide additional opportunities to develop complementary therapies that target the inflammatory microenvironment of CRC.
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CRC

:   colorectal cancer

GC

:   gastric cancer

IgG

:   immunoglobulin G

OR

:   odds ratio

CI

:   confidence intervals

ELISA

:   enzyme-linked immunosorbent assay

Hp

:   Helicobacter pylori

PG

:   pepsinogen

G-17

:   gastrin 17

IM

:   intestinal metaplasia

ENTD

:   extranodal tumor deposits

###### 

Baseline characteristics of the study participants

  ---------------------------------------------------------------------------
  Indexes           CRC                 Controls            CRC vs Controls
  ----------------- ------------------- ------------------- -----------------
  Age (years,\      62.0±11.0           60.8±9.6            0.055
  mean ± SD)                                                

  Gender                                                    

  Male              331(58.2)           304(53.4)           0.107

  Female            238(41.8)           265(46.6)           

  PGI (ug/L) ^b^    99.9(78.2\~132.3)   82.3(65.5\~100.4)   

  PGII (ug/L) ^b^   9.7(6.4\~15.6)      7.6(6.0\~11.0)      

  PGI/II ^b^        10.6(7.2\~14.3)     9.8(7.7\~13.4)      

  G17(pmol/L) ^b^   2.9(0.8\~8.6)       2.1(0.5\~3.9)       

  *Hp-*IgG          265(46.6)           205(36.0)           
  ---------------------------------------------------------------------------

a: Data are expressed as frequency and percentages.

b: Data are expressed as median (25th to 75th percentiles).

###### 

Association of serum markers reflecting gastric function and *H. pylori* infection with CRC risk

  Indexes                CRC              Controls         CRC vs Controls   
  ---------------------- ---------------- ---------------- ----------------- --------------------
  PGI^+^ /PGI^-^         106/463(18.63)   133/436(23.37)   0.096             0.78(0.58-1.05)
  PGII^+^ /PGII^-^       339/230(59.58)   278/291(48.86)   **0.006**         1.49(1.17-1.90)
  PGI/II^+^ /PGI/II^-^   134/435(23.55)   127/442(22.32)   0.650             1.07(0.81-1.41)
  G-17^+^ /G-17^-^       197/372(34.62)   124/445(21.79)   **\<0.001^c^**    1.77(1.34-2.32)^c^
  *Hp*^+^ /*Hp*^-^       265/304(46.57)   205/364(36.03)   **0.001**         1.56(1.22-1.97)

a: Percentages of positivity.

b: Adjusted by age and sex.

c: Adjusted by age, sex and *Hp-*IgG.

###### 

Association of serum markers reflecting gastric function and *H. pylori* infection with CRC risk in subgroups

  ------------- ---------------------- ------------------ ---------------------- ------------- ----------------- --------- --------------- ------------- ----------------- --------- --------------- ------------- ----------------- --
                **PGI+ /PGI-**         **PGII+ /PGII-**   **PGI/II+ /PGI/II-**                                                                                                                                                       
  **CRC**       **Controls**           ***P***            **OR(95%CI)**          **CRC**       **Controls**      ***P***   **OR(95%CI)**   **CRC**       **Controls**      ***P***   **OR(95%CI)**                                   
  Age ^a^                                                                                                                                                                                                                            
                ≥60                    56/274             70/269                 0.269         0.80(0.54-1.19)   223/107   194/145         **0.033**     1.55(1.13-2.12)   89/241    88/251          0.672         1.08(0.76-1.52)   
                \<60                   50/189             63/167                 0.131         0.72(0.46-1.11)   116/123   84/146          **0.049**     1.63(1.12-2.36)   45/194    39/191          0.501         1.18(0.73-1.91)   
  Gender ^b^                                                                                                                                                                                                                         
                Male                   47/284             55/249                 0.176         0.75(0.49-1.14)   205/126   152/152         **0.014**     1.63(1.18-2.25)   60/271    57/247          0.784         0.95(0.63-1.42)   
                Female                 59/179             78/187                 0.415         0.85(0.57-1.27)   134/104   126/139         0.159         1.30(0.90-1.87)   74/164    70/195          0.354         1.20(0.81-1.78)   
  *Hp-*IgG^c^                                                                                                                                                                                                                        
                \+                     47/218             31/174                 0.411         1.23(0.75-2.03)   179/86    172/33          **\<0.001**   0.37(0.23-0.59)   72/193    103/102         **\<0.001**   0.36(0.24-0.53)   
                \-                     59/245             102/262                **0.126**     0.65(0.45-0.95)   160/144   106/258         **\<0.001**   2.63(1.89-3.65)   62/242    24/340          **\<0.001**   3.65(2.20-6.05)   
                                                                                                                                                                                                                                     
                **G-17^+^ /G-17^-^**   ***Hp*+ /*Hp*-**                                                                                                                                                                              
  **CRC**       **Controls**           ***P***            **OR(95%CI)**          **CRC**       **Controls**      ***P***   **OR(95%CI)**                                                                                             
  Age ^a^                                                                                                                                                                                                                            
                ≥60                    118/212            82/257                 **0.004**     1.78(1.27-2.50)   154/176   136/203         0.064         1.34(0.98-1.82)                                                             
                \<60                   79/160             42/188                 **0.001**     2.25(1.46-3.46)   111/128   69/161          **0.001**     2.03(1.39-2.96)                                                             
  Gender ^b^                                                                                                                                                                                                                         
                Male                   107/224            55/249                 **\<0.001**   2.16(1.49-3.13)   145/186   102/202         **0.042**     1.54(1.12-2.13)                                                             
                Female                 90/148             69/196                 **0.033**     1.70(1.16-2.48)   120/118   103/162         0.076         1.56(1.09-2.22)                                                             
  *Hp-*IgG^c^                                                                                                                                                                                                                        
                \+                     114/151            85/120                 0.639         1.09(0.75-1.59)   ---                                                                                                                 
                \-                     83/221             39/325                 **\<0.001**   3.10(2.04-4.71)                                                                                                                       
                                                                                                                                                                                                                                     
  ------------- ---------------------- ------------------ ---------------------- ------------- ----------------- --------- --------------- ------------- ----------------- --------- --------------- ------------- ----------------- --

a: Adjusted by sex.

b: Adjusted by age.

c: Adjusted by age and sex.

###### 

Association of serum markers reflecting gastric function and*H. pylori* infection with tumor biomarkers

  -------------- ------------ -------------- --------------- ----------- ------------------ ------------ --------------- ----------- ------------------ ------------ --------------- ------- -----------------
                 **PGI**      **PGII**       **PGI/II**                                                                                                                                      
  **+/-**        **(%^b^)**   ***P*^a^**     **OR(95%CI)**   **+/-**     **(%^b^)**         ***P*^a^**   **OR(95%CI)**   **+/-**     **(%^b^)**         ***P*^a^**   **OR(95%CI)**           
  CEA(N=429)     \+           36/153         19.05           0.991       1.00(0.61-1.64)    111/78       58.73           0.894       1.03(0.69-1.53)    33/156       17.46           0.203   0.73(0.45-1.19)
  \-             46/194       19.17          140/100         58.33       55/185             22.92                                                                                            
  AFP(N=426)     \+           2/11           15.38           0.601       0.66(0.14-3.11)    8/5          61.54           0.489       1.52(0.47-4.92)    4/9          30.77           0.237   2.13(0.61-7.48)
  \-             78/335       18.89          241/172         58.35       82/331             19.85                                                                                            
  CA125(N=428)   \+           5/17           22.73           0.402       1.57(0.55-4.54)    16/6         72.73           0.446       1.47(0.55-3.93)    3/19         13.64           0.373   0.57(0.16-1.99)
  \-             77/329       18.97          234/172         57.64       85/321             20.94                                                                                            
  CA153(N=424)   \+           0/8            0               NA          NA                 5/3          62.50           0.983       1.02(0.23-4.45)    1/7          12.50           0.552   0.53(0.06-4.38)
  \-             80/336       19.23          244/172         58.65       86/330             20.67                                                                                            
  CA199(N=428)   \+           24/85          22.02           0.452       1.23(0.72-2.13)    58/51        53.21           0.185       0.74(0.47-1.16)    20/89        18.35           0.354   0.77(0.44-1.35)
  \-             57/262       17.87          193/126         60.50       67/252             21.00                                                                                            
                                                                                                                                                                                             
                 **G17**      ***Hp-*IgG**                                                                                                                                                   
  **+/-**        **(%^b^)**   ***P*^a^**     **OR(95%CI)**   **+/-**     **(%^b^)**         ***P*^a^**   **OR(95%CI)**                                                                       
  CEA(N=429)     \+           62/127         32.80           0.407       0.84(0.56-1.26)    89/100       47.09           0.129       1.35(0.92-1.98)                                         
  \-             88/152       36.67          96/144          40.00                                                                                                                           
  AFP(N=426)     \+           4/9            30.77           0.707       0.79(0.24-2.64)    5/8          38.46           0.750       0.83(0.27-2.60)                                         
  \-             145/268      35.11          179/234         43.34                                                                                                                           
  CA125(N=428)   \+           15/7           68.18           **0.005**   4.89(1.90-12.57)   16/6         72.73           **0.024**   4.10(1.54-10.93)                                        
  \-             135/271      33.25          169/237         41.63                                                                                                                           
  CA153(N=424)   \+           5/3            62.50           0.102       3.35(0.79-14.30)   3/5          37.50           0.747       0.79(0.18-3.36)                                         
  \-             142/274      34.13          180/236         43.27                                                                                                                           
  CA199(N=428)   \+           32/77          29.36           0.154       0.71(0.44-1.14)    45/64        41.28           0.534       0.87(0.56-1.36)                                         
  \-             117/202      36.68          140/179         43.89                                                                                                                           
  -------------- ------------ -------------- --------------- ----------- ------------------ ------------ --------------- ----------- ------------------ ------------ --------------- ------- -----------------

a: Adjusted by age and sex.

b: Percentages of positivity.

NA: Not available.

[^1]: Competing Interests: The authors have declared that no competing interest exists.
